期刊文献+

注射用奥沙利铂与不同输液配伍的稳定性 被引量:18

Stability of compatibility between oxaliplatin injection and different infusions
下载PDF
导出
摘要 目的:考察注射用奥沙利铂与葡萄糖注射液、木糖醇注射液以及果糖注射液配伍后的稳定性。方法:考察注射用奥沙利铂与葡萄糖注射液(GS)、木糖醇注射液及果糖注射液配伍后溶液的外观性状、pH值及含量等。结果:注射用奥沙利铂与葡葡糖注射液及果糖注射液配伍8 h,其含量均在95%以上,外观性状及pH值均无明显变化;注射用奥沙利铂与木糖醇注射液配伍8 h,pH值、含量逐渐降低。结论:注射用奥沙利铂在临床应用时宜采用葡萄糖注射液及果糖注射液进行配伍使用,不宜与木糖醇注射液配伍使用。 Objective:To investigate the stability of compatibility between oxaliplatin injection and glucose Infusion,or xylitol infusion,or fructose infusion. Methods:To observe solutions appearance , pH values, oxaliplatin level and etc., following compatibilities testing of oxaliplatin injection with glucose infusion,xylitol infusion,and fructose infusion. Results: After 8 hours compatibility testing between both oxaliplatin for injection and glucose infusion as well as oxaliplatin injection and fructose infusion, the contents of each maintain more than 95%. Their appearance, properties and pH values have no significant change. After 8 hours compatibility between oxaliplatin injection and xylitol infusion, the solutions pH values and content were gradually decreased.Conclusion:ln clinical application, oxaliplatin injection should adopt glucose infusion and fructose infusion rather than xylitol infusion for compatibility.
出处 《抗感染药学》 2005年第2期87-88,共2页 Anti-infection Pharmacy
基金 2003年江苏奥赛康医药研究基金资助项目(编号:2003-13)
关键词 注射用奥沙利铂 输液 高效液相色谱法 稳定性 Oxaliplatin for Injection Infusion High Performance Liquid Chromatography Stability
  • 相关文献

参考文献4

二级参考文献26

  • 1Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J].Lancet, 2000, 355(9209): 1041-1047.
  • 2Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel[J].Biochem Pharmacol, 1996,5
  • 3Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J].J Clin Oncol, 2000, l8(1): 136-147.
  • 4Wasserman E, Cuvier C, Lokeic F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase Ⅰ studies with pharmacokinetics[J]. J Clin Oncol, 1999,17(6): 1751-1759.
  • 5Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer[J]. J Clin Oncol, 1999, 17(3): 902-906.
  • 6Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22(1): 23-30.
  • 7Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J]. Lancet, 1998, 352(9138): 1413-1418.
  • 8Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer[J].Lancet, 1998, 352(9138): 1407-1412.
  • 9Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J].J Clin Oncol, 2003, 21(1): 60-65.
  • 10Cuningham D, Humblet Y, Siena S, et al. Cetuximab alone or in combination with irinotecan in patients with epidermal growth-factor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer[C]. Proc Am Soc Clin Oncol, 2003, Abstract :1012.

共引文献50

同被引文献209

引证文献18

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部